Eloxx Pharmaceuticals has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500.
Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Eloxx Pharmaceuticals and its peers revenue, earnings per share and valuation.
Eloxx Pharmaceuticals (NASDAQ: ELOX) is one of 40 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its peers?
Comparatively, Eloxx Pharmaceuticals’ peers have a beta of 5.75, suggesting that their average share price is 475% more volatile than the S&P 500.